THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Salajka, Frantisek [1 ]
Pesek, Milos [2 ]
Krejci, Jana [3 ]
Skrickova, Jana [4 ]
Zatloukal, Petr
Koubkova, Leona
Grygarkova, Ivona
Hrnciarik, Michal [1 ]
Sticha, Michal [5 ]
机构：
[1] Univ Hosp, Dept Pneumol, Bulovka, Czech Republic
[2] Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[3] Charles Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[4] Univ Hosp Brno, Dept Resp Dis & Tb, Brno, Czech Republic
[5] Masaryk Univ, CS-60177 Brno, Czech Republic
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; erlotinib; clinical predictors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1293 / S1294
页数：2
相关论文
共 50 条
  • [21] Rational selection of biomarkers to help direct erlotinib treatment for advanced non-small cell lung cancer (NSCLC)
    Borgia, Jeffrey A.
    Frankenberger, Casey
    Basu, Sanjib
    Rouhi, Omid
    Fidler, Mary J.
    Batus, Marta
    Fhied, Cristina L.
    Dalovisio, Andrew P.
    Lie, Wen-Rong
    Maheshwari, Reeti
    Hayes, David
    Coon, John
    Bonomi, Philip
    CANCER RESEARCH, 2011, 71
  • [22] IMPROVING TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4038 - 4038
  • [23] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [24] Retrospective Analysis of Clinical Efficacy of Erlotinib in Patients with Non-Small Cell Lung Cancer
    Ayyildiz, Aylin
    Kanat, Ozkan
    Ozkaya, Guven
    Deligonul, Adem
    Gursoy, Vildan
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2015, 6 (02) : 212 - 215
  • [25] Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
    Wang, Yongsheng
    Schmid-Bindert, Gerald
    Zhou, Caicun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (01) : 19 - 29
  • [26] Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
    Neumair, P.
    Joos, L.
    Warschkow, R.
    Ess, S.
    Hitz, F.
    Frueh, M.
    Brutsche, M. H.
    Baty, F.
    Krahenbuhl, S.
    Jorger, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S131 - S131
  • [27] Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.
    Fidler, M. J.
    Argiris, A.
    Patel, J. D.
    Johnson, D. H.
    Sandler, A.
    Villaflor, V.
    Coon, J.
    Buckingham, L.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 407S - 407S
  • [28] Erlotinib in the treatment of non-small cell lung cancer
    Brown, Ewan R.
    Shepherd, Frances A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 767 - 775
  • [29] From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy
    Mazzoni, Francesca
    Rotella, Virginia
    Pratesi, Nicola
    Boni, Luca
    Simi, Lisa
    Orlando, Claudio
    Comin, Camilla Eva
    Maddau, Cristina
    Di Costanzo, Francesco
    TUMORI JOURNAL, 2011, 97 (02): : 160 - 165
  • [30] Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    Ramlau, Rodryg
    Jaskiewicz, Piotr
    Janowicz-Zebrowska, Anna
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (02): : 170 - 175
12345